[Herpes simplex virus (hsv-1 and hsv-2) infection: its clinical and oncogenic properties (author's transl)].
The epidemiology and clinical features of diseases caused by the herpes simplex virus, are reviewed and recent results are discussed which give an insight into the complex mechanism of primary and chronic, recurrent HSV-1 infections. Immunological reactions in HSV infection and data concerning the oncogenic potential of HSV-1 and -2 are dealt with. Furthermore, current therapeutic possibilities are outlined.
D000547:Amantadine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D000917:Antibody Formation; D000936:Antigen-Antibody Complex; D001500:BCG Vaccine; D002471:Cell Transformation, Neoplastic; D003176:Complement C3 / Q000172:deficiency; D003561:Cytarabine / Q000627:therapeutic use; D004279:DNA, Viral; D005260:Female; D005724:Ganglia / Q000382:microbiology; D005831:Genital Diseases, Female / Q000473:pathology; D005832:Genital Diseases, Male / Q000473:pathology; D000882:Haplorhini; D006560:Herpes Labialis / Q000473:pathology; D006561:Herpes Simplex; D004854:Herpesvirus 4, Human / Q000472:pathogenicity; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007111:Immunity, Cellular; D007978:Levamisole / Q000627:therapeutic use; D008297:Male; D011370:Proflavine / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000209:etiology; D011817:Rabbits; D002583:Uterine Cervical Neoplasms / Q000209:etiology; D014740:Vidarabine / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use
D000936:Antigen-Antibody Complex; D001500:BCG Vaccine; D003176:Complement C3; D004279:DNA, Viral; D014765:Viral Vaccines; D003561:Cytarabine; D007978:Levamisole; D000547:Amantadine; D011370:Proflavine; D014740:Vidarabine; D007065:Idoxuridine
Die Herpes-simplex-Virus-(HSV-1-und HSV-2-) Infektion- ihre klinische und onkogene Bedeutung.